Advanced Enzyme Technologies reported a 2% year-on-year revenue increase to ₹189.8 crore for Q1 FY27. However, EBITDA fell 10% and net profit declined 5% year-on-year. Growth was driven by specialized segments, while core nutrition divisions saw a dip.
Advanced Enzyme Technologies Reports Mixed Q1 FY27 Results
Advanced Enzyme Technologies' revenue for the first quarter of FY27 reached ₹189.8 crore, marking a 2% increase compared to the same period last year. However, the company's profitability faced pressure, with EBITDA seeing a 10% year-on-year decline to ₹51.0 crore and net profit falling by 5% to ₹38.6 crore.
Reader Takeaway: Niche segments show strong growth, but core nutrition divisions face sequential and year-on-year declines.
What just happened
Advanced Enzyme Technologies announced its financial results for Q1 FY27. Consolidated revenue from operations stood at ₹189.8 crore, a 2% increase from ₹185.9 crore in Q1 FY26. EBITDA was reported at ₹51.0 crore, down from ₹56.4 crore in the prior year's comparable quarter. Net profit after tax (PAT) was ₹38.6 crore, a decrease from ₹40.4 crore in Q1 FY26.
The company noted a sequential revenue decline of 7% to ₹189.8 crore from ₹203.4 crore in the previous quarter. Profitability also saw a sequential drop, with EBITDA down 19% and PAT down 15% quarter-on-quarter.
Why this matters
The mixed results indicate growth in specific business areas while highlighting challenges in others. The sequential de-growth suggests potential short-term headwinds that investors will want to understand. The contrast between the strong performance of industrial segments and the decline in core nutrition businesses presents a complex picture for the company's overall trajectory.
The backstory
Advanced Enzyme Technologies is a leading global company in the research, development, and manufacturing of enzyme-based solutions. It serves various industries including human nutrition, animal nutrition, and industrial bio-processing.
What changes now
Investors will be closely watching management's commentary for insights into the drivers behind the sequential de-growth and the sustainability of growth in the specialized segments. The company's ability to navigate these divergent performances will be crucial for its future stock performance.
Risks to watch
The primary concerns are the sequential decline in revenue and profits, and the year-on-year decrease in the core Human Nutrition and Animal Nutrition segments. Sustained weakness in these core areas could impact overall volume stability and future growth.
Segment Analysis
Human Nutrition, representing 60% of Q1 FY27 sales, saw a 7% year-on-year revenue decline. Animal Nutrition revenue also dipped by 3% year-on-year. However, Industrial Bio-processing and Specialized Manufacturing emerged as growth engines, with revenue surging 30% and 41% year-on-year, respectively.
Geographically, the company reported strong growth in Europe (+44% Y-o-Y) and Asia (excluding India) (+37% Y-o-Y), indicating positive traction in key international markets.
Context metrics (time-bound)
- Q1 FY27 Revenue: ₹189.8 crore (+2% YoY, -7% QoQ)
- Q1 FY27 EBITDA: ₹51.0 crore (-10% YoY, -19% QoQ)
- Q1 FY27 Net Profit: ₹38.6 crore (-5% YoY, -15% QoQ)
- Human Nutrition Revenue: ₹113.9 crore (-7% YoY)
- Animal Nutrition Revenue: ₹25.2 crore (-3% YoY)
- Industrial Bio-processing Revenue: ₹30.6 crore (+30% YoY)
- Specialized Manufacturing Revenue: ₹20.0 crore (+41% YoY)
- European Market Growth: +44% YoY
- Asian Market Growth (ex-India): +37% YoY